Stool Transplant to Help Prevent Complications After Stem Cell Transplant
Tests a donor stool transplant in adults with blood cancers after stem cell transplant.
Plain-language title generated from the registry record
Registry title: Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
Key facts
- Where
- Amiens, Angers, Besançon, Clermont-Ferrand, Grenoble, Lille, Limoges, Lyon, Nancy, Nantes, Nice, Paris, Pessac, Poitiers, Rouen, Saint-Etienne, and Toulouse, FranceSee the 20 sites
- Phase
- Phase 2
Where in France
- Service d'Hématologie Clinique et Thérapie Cellulaire CHU Amiens Picardie - Site SudAmiens, FranceNot yet recruiting
- Service Maladies du sang CHU AngersAngers, FranceNot yet recruiting
- Hématologie clinique CHU BesançonBesançon, FranceNot yet recruiting
- Plateforme d'Investigation Clinique / Centre d'Investigation Clinique - Inserm 1405, CHU Gabriel Montpied Clermont-FerrandClermont-Ferrand, FranceTaking people
- Service de thérapie Cellulaire et d'Hématologie Clinique Adulte CHU Estaing - Clermont-FerrandClermont-Ferrand, FranceNot yet recruiting
- Service hématologie CHU GrenobleGrenoble, FranceNot yet recruiting
- Service des Maladies du sang Hôpital HURIEZ, CHRU de LilleLille, FranceNot yet recruiting
- Service de thérapie cellulaire et l'hématologie clinique adulte CHU LimogesLimoges, FranceTaking people
- Service d'Hématologie Centre Hospitalier Lyon SudLyon, FranceNot yet recruiting
- Service d'Hématologie et de Médecine interne Hôpital Brabois CHRU NancyNancy, FranceNot yet recruiting
- Service d'Hématologie Clinique CHU NantesNantes, FranceNot yet recruiting
- Service d'hématologie clinique, département de greffe de moelle CHU NiceNice, FranceNot yet recruiting
- Service d'Hématologie Adultes Hôpital NeckerParis, FranceTaking people
- Service d'Hématologie clinique Hôpital Pitié-SalpêtrièreParis, FranceNot yet recruiting
- Service d'hématologie greffe Hôpital St LouisParis, FranceNot yet recruiting
- Hématologie clinique et thérapie cellulaire Hôpital Haut-LévèquePessac, FranceNot yet recruiting
- Service d'hématologie greffe Hôpital St LouisPoitiers, FranceNot yet recruiting
- Département d'hématologie CAC RouenRouen, FranceNot yet recruiting
- Hématologie clinique Institut de Cancérologie de la LoireSaint-Etienne, FranceNot yet recruiting
- IUC T - OncopôleToulouse, FranceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Clermont-Ferrand
- Trial code
- NCT04935684
- Record updated
- 21 September 2026
- Original description
The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic hematopoietic stem cell transplantation (allo-HSCT) complications and particularly Graft versus Host Disease (GvHD).Read full original descriptionShow less
Faecal Microbiota Transplantation for Prevention of Graft-versus-host Sisease After Allogeneic Stem Cell Transplantation for Haematological Malignancies
The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic hematopoietic stem cell transplantation (allo-HSCT) complications and particularly Graft versus Host Disease (GvHD).
The hypothesis of this study is that allogeneic FMT may improve outcomes of these patients.
Inclusion: Patient aged 18 or over; Men and women; Patients affiliated with a social-security organization; Patients undergoing a myelo-ablative allo-HSCT for a controlled haematologic malignant disease, with peripheral stem cells, whatever the type of donor (except cord blood); Signed and dated informed consent.
Exclusion: Medical history of another progressive cancer or occurrence in the 3 previous years (excluding basal cell carcinoma); Presence of a simultaneous serious and uncontrolled disease (severe cardiac, renal, hepatic or respiratory failure, severe sepsis); Status of tumor progression at the time of allo-HSCT; Inability to understand the protocol (linguistic barrier, cognitive difficulties); Fecal incontinence; Participation in another clinical trial studying an allograft procedure including the type of graft, the type of immunosuppression, a preventive or a curative treatment of GvHD, or studying the effectiveness of a FMT in another indication; Pregnant women; Patient under guardianship, curatorship or protection of justice.